Argos Therapeutics Inc fka ARGSQ

[Schnauzer1]

Nervous Investors is reason for stock decline! IDCM review should have been announced, so fact is this is the 50% interim review (IDMC did not have to say when that would occur). That gives a lot of information to investors. At this point the IDMC must review data and determine whether it would be futile to continue trial! If the Committee gives the go forward signal to the company, then this stock should gain substantial value, and stock price. Alternatively, if the next thing you hear is the company announcing a futility finding, well...